Literature DB >> 22517556

High incidence of cardiovascular complications in pheochromocytoma.

T Zelinka1, O Petrák, H Turková, R Holaj, B Strauch, M Kršek, A B Vránková, Z Musil, J Dušková, J Kubinyi, D Michalský, K Novák, J Widimský.   

Abstract

Excess of catecholamines in pheochromocytoma is usually accompanied with classical symptoms and signs. In some cases, severe cardiovascular complications (e. g., heart failure, myocardial infarction) may occur. We performed a retrospective analysis focused on the incidence of cardiovascular complications (classified as follows: arrhythmias, myocardial involvement or ischemia and atherosclerosis, cerebrovascular impairment) before the establishment of diagnosis of pheochromocytoma among 145 subjects treated in our hospital. Cardiovascular complications occurred in 28 subjects, but these subjects did not differ significantly from subjects without complications in age, gender, body mass index, paroxysmal symptoms, symptom duration, tumor dimension, catecholamine secretory phenotype, and incidence of hypertension or diabetes mellitus. Arrhythmias occurred in 15 subjects (2 arrhythmia types in 2 subjects): atrial fibrillation in 9 subjects, supraventricular tachycardia in 3 cases, and ventricular tachycardia in 2 patients. Significant bradycardia was noted in 3 cases. Five subjects presented with heart failure with decreased systolic function (takotsubo-like cardiomyopathy found in 2 cases). One subject suffered from hypertrophic obstructive cardiomyopathy. Seven subjects presented with non-ST-segment elevation myocardial infarction, 2 patients with ST-segment myocardial infarction, and 1 subject underwent coronary artery bypass grafting. Two subjects suffered from significant peripheral atherosclerosis. Among cerebrovascular complications, transient ischemic attack was found in 3 cases, 2 subjects suffered from stroke, and subarachnoidal bleeding occurred in 1 patient. One subject suffered from diffuse neurological impairment due to multiple ischemic white matter lesions. These data show relatively high incidence of cardiovascular complications (19.3%) in subjects with pheochromocytoma. Early diagnosis is mandatory to prevent severe complications in pheochromocytoma. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22517556     DOI: 10.1055/s-0032-1306294

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  43 in total

1.  Pheochromocytoma and Paraganglioma: progress on all fronts.

Authors:  Anne-Paule Gimenez-Roqueplo; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

2.  HSP70 inhibitor VER155008 suppresses pheochromocytoma cell and xenograft growth by inhibition of PI3K/AKT/mTOR and MEK/ERK pathways.

Authors:  Feifei Xu; Dengqiang Lin; Wen Jiang; Li Meng; Yunze Xu; Chenghe Wang; Xiaojing Wang; Hongchao He; Danfeng Xu; Yu Zhu
Journal:  Int J Clin Exp Pathol       Date:  2019-07-01

Review 3.  Pathophysiology and Acute Management of Tachyarrhythmias in Pheochromocytoma: JACC Review Topic of the Week.

Authors:  Matthew A Nazari; Jared S Rosenblum; Mark C Haigney; Douglas R Rosing; Karel Pacak
Journal:  J Am Coll Cardiol       Date:  2020-07-28       Impact factor: 24.094

4.  Embolisation of pheochromocytoma to stabilise and wean a patient in cardiogenic shock from emergency extracorporeal life support.

Authors:  Helle Vagner; Thomas Morris Hey; Bo Elle; Marianne Kjær Jensen
Journal:  BMJ Case Rep       Date:  2015-03-03

5.  Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association.

Authors:  Karen Gomez Hernandez; Shereen Ezzat; Chantal F Morel; Carol Swallow; Mirek Otremba; Brendan C Dickson; Sylvia L Asa; Ozgur Mete
Journal:  Virchows Arch       Date:  2015-03-24       Impact factor: 4.064

Review 6.  Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma.

Authors:  Camilo Jimenez; Eric Rohren; Mouhammed Amir Habra; Thereasa Rich; Paola Jimenez; Montserrat Ayala-Ramirez; Eric Baudin
Journal:  Curr Oncol Rep       Date:  2013-08       Impact factor: 5.075

7.  Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?

Authors:  Ryan J Ellis; Dhaval Patel; Tamara Prodanov; Samira Sadowski; Naris Nilubol; Karen Adams; Seth M Steinberg; Karel Pacak; Electron Kebebew
Journal:  J Am Coll Surg       Date:  2013-07-25       Impact factor: 6.113

8.  Giant phaeochromocytoma presenting with an acute stroke: reappraising phaeochromocytoma surveillance for the neurofibromatosis type 1 phakomatosis.

Authors:  Yingshan Lee; Leon Yuan Rui Tan; Yong Howe Ho; Melvin Khee Shing Leow
Journal:  BMJ Case Rep       Date:  2017-11-03

9.  Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo.

Authors:  Dengqiang Lin; Xiaoxia Li; Lieyu Xu; Jianpo Lian; Yunze Xu; Li Meng; Xin Xie; Xiaojing Wang; Hongchao He; Danfeng Xu; Chenghe Wang; Yu Zhu
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 10.  Atrial Fibrillation and Its Association with Endocrine Disorders.

Authors:  Manjari Devidi; Avanija Buddam; Sunil Dacha; D Sudhaker Rao
Journal:  J Atr Fibrillation       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.